NAE-IN-4
NAE-IN-4 is an orally active Nedd8-activating enzyme (NAE) inhibitor with a Kd of 12.80 μM for NAE. NAE-IN-4 antagonizes β1AR, contributing to cardioprotective effects, shows weaker antagonism of β2AR, and weakly inhibits the hERG potassium channel. NAE-IN-4 induces apoptosis (Apoptosis) and inhibits the accumulation of ROS. NAE-IN-4 attenuates Doxorubicin (HY-15142A)-induced cardiotoxicity and enhances the antitumor effect of Doxorubicin in tumor-bearing mice with heart failure. NAE-IN-4 can be used for research on lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 3124331-57-0
- Formula: C28H35N3O3
- Molecular Weight:461.60
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Adrenergic Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Beta-1 adrenergic receptor |
Beta-2 adrenergic receptor |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2.61 μM
|
Antiproliferative activity against human A549 lung cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human A549 lung cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42962313 |
| NCI-H1299 | IC50 |
2.98 μM
|
Antiproliferative activity against human H1299 lung cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human H1299 lung cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42962313 |
| Huh-7 | IC50 |
0.87 μM
|
Antiproliferative activity against human Huh-7 hepatocellular carcinoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human Huh-7 hepatocellular carcinoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42962313 |
| HepG2 | IC50 |
0.66 μM
|
Antiproliferative activity against human HepG2 hepatocellular carcinoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human HepG2 hepatocellular carcinoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42962313 |
| RKO | IC50 |
1.06 μM
|
Antiproliferative activity against human RKO colorectal carcinoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human RKO colorectal carcinoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42962313 |
| HCT-116 | IC50 |
1.26 μM
|
Antiproliferative activity against human HCT116 colorectal carcinoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human HCT116 colorectal carcinoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42962313 |
| A 172 | IC50 |
2.23 μM
|
Antiproliferative activity against human A172 glioblastoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human A172 glioblastoma cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42962313 |
| H9c2 | IC50 |
6.05 μM
|
Antiproliferative activity against rat H9c2 cardiomyocytes assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against rat H9c2 cardiomyocytes assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42962313 |
| BEAS-2B | IC50 |
5.33 μM
|
Antiproliferative activity against human BEAS-2B bronchial epithelial cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human BEAS-2B bronchial epithelial cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42962313 |
In Vitro
NAE-IN-4 (0.4-10 µM; 8 h) inhibits cullin neddylation and global Nedd8 modification in A549 and H1299 cells without reducing NAE1 levels[1].
NAE-IN-4 (72 h) inhibits cancer cell proliferation with IC50 values of 0.66-2.98 µM, and shows lower potency in normal H9c2 and BEAS-2B cells (5.33-6.05 µM)[1].
NAE-IN-4 (10 µM; 12 h) selectively binds to NAE and thermostabilizes it in A549 cells, but does not bind UBE2M[1].
NAE-IN-4 (72 h) mediates antiproliferative effects in A549 and H1299 cells, which are attenuated by NAE knockdown, whereas UBE2M knockdown does not attenuate this effect[1].
NAE-IN-4 (0.1-1 µM; 10-14 days) inhibits colony formation in A549 and H1299 cells in a concentration-dependent manner[1].
NAE-IN-4 shows weak inhibition of hERG, with an IC50 of 7.8 µM[1].
NAE-IN-4 inhibits CYP1A2 and CYP2D6 with IC50 values of 15.3 and 8.2 µM, respectively, and shows IC50 > 30 µM against the other tested CYP isoforms[1].
NAE-IN-4 exhibits good liver microsomal and plasma stability, with t1/2 > 120 min in both assays[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:5 µM
-
Incubation Time:8 h
-
Result:Inhibited CUL1-Nedd8 adduct formation by 80.60%.
-
Cell Line:A549 and H1299 cells
-
Concentration:0.4, 1.1, 3.3, 10 µM
-
Incubation Time:8 h
-
Result:Inhibited CUL1-Nedd8, CUL2-Nedd8, CUL3-Nedd8, CUL4a-Nedd8, and CUL5-Nedd8 adduct formation and decreased global Nedd8 modification in a concentration-dependent manner, without affecting NAE1 protein levels.
-
Cell Line:A549 and H1299 cells
-
Concentration:0.1, 0.3, 1 µM
-
Incubation Time:10-14 days
-
Result:Inhibited colony formation in A549 and H1299 cells in a concentration-dependent manner.
-
Cell Line:A549 and H1299 cells
-
Concentration:1.1, 3.3, 10 µM
-
Incubation Time:48 h
-
Result:Apoptotic fractions increased dose-dependently.
In A549, upper-right Annexin V/PI fractions were 3.4%, 5.9%, and 14.0% at 1.1, 3.3, and 10 µM.
In H1299, upper-right fractions were 3.2%, 6.3%, and 15.3% at 1.1, 3.3, and 10 µM.
-
Cell Line:H9c2 cells
-
Concentration:1 µM (Compound 28); 2.5 µM (DOX)
-
Incubation Time:12 h (Compound 28); 6 h (DOX); 6 h (hypoxia); 12 h (reoxygenation)
-
Result:H9c2 viability rate was 58.3% in the DOX model and 45.6% in the H/R model.
Parmacokinetics
In Vivo
NAE-IN-4 (20-40 mg/kg; p.o.; q.d.; five consecutive days per week with two-day rest; 28 days) suppresses A549 xenograft growth dose-dependently, with TGI of 52.3% at 20 mg/kg and 74.3% at 40 mg/kg in female nude mice[1].
NAE-IN-4 (40 mg/kg; p.o.; q.d.; five consecutive days per week with two-day rest; 21 days) suppresses H1299 xenograft growth in nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:nude (female)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; q.d.; five consecutive days per week with two-day rest; until day 27
-
Result:Produced a tumor growth inhibition rate of 77.02% after 27 days.
-
Animal Model:nude (female)[1]
-
Dosage:20 mg/kg; 40 mg/kg
-
Administration:p.o.; q.d.; five consecutive days per week with two-day rest; 28 days
-
Result:Produced TGI of 52.3% at 20 mg/kg and 74.3% at 40 mg/kg after 28 days.
Reduced CUL1-Nedd8 and global neddylation protein levels in vivo.
-
Animal Model:nude (female)[1]
-
Dosage:40 mg/kg
-
Administration:p.o.; q.d.; five consecutive days per week with two-day rest; 21 days
-
Result:Inhibited H1299 xenograft growth in vivo without affecting mouse body weight.
-
Animal Model:C57[1]
-
Dosage:40 mg/kg
-
Administration:p.o.; q.o.d.; single-agent and DOX combination; six-day dosing with one-day rest; three weeks
-
Result:Partially reversed DOX-induced changes in body and heart weights.
Improved DOX-induced interstitial edema and collagen deposition.
Echocardiography showed restored LVEF and LVFS, and DOX-induced increases in LVDd and LVDs were attenuated; cardiac output was restored.
-
Animal Model:nude (female)[1]
-
Dosage:40 mg/kg
-
Administration:p.o.; t.i.w.; single-agent and DOX combination; six-day cycle with one-day rest
-
Result:The combination with DOX exhibited superior anticancer activity to single-agent groups and produced smaller weight loss than DOX alone.
Partially reversed DOX-induced reductions in heart weight and volume.
Alleviated heart deterioration and suppressed the adverse cardiac phenotype induced by DOX.
Echocardiography showed restored LVEF and LVFS, and DOX-induced increases in LVDd and LVDs were inhibited.
Decreased DOX-elevated CK and LDH and partially ameliorated DOX-induced liver and kidney dysfunction.
Chemical Information
-
CAS No. 3124331-57-0
-
Molecular Weight 461.60
-
Formula C28H35N3O3
-
SMILES
OC(CN[C@H]1CC[C@H](NC2=CC=CC=C2OC)CC1)COC3=CC=C(NC4=CC=CC=C4)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- NAE-IN-4
- 3124331-57-0
- NEDD8-activating Enzyme
- Adrenergic Receptor
- Potassium Channel
- Apoptosis
- Reactive Oxygen Species (ROS)
- NAE
- Beta Receptor
- KcsA
- Nedd8-activating enzyme
- apoptosis
- doxorubicin-induced cardiotoxicity
- hERG potassium channel
- lung cancer
- neddylation
- reactive oxygen species
- xenograft
- β1AR
- β2AR
- Inhibitor
- inhibitor
- inhibit